Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tredaptive Safety Hazards Cast Shadow Over AbbVie’s Niaspan

Executive Summary

HPS2-THRIVE investigators say serious adverse bleeding and infection events are most likely due to the niacin component of Merck’s Tredaptive and advise caution using niacin in light of the risks. Abbvie’s Niaspan is the most likely branded casualty of the news, but the drug will be off-patent soon.

Advertisement

Related Content

New Cholesterol Guidelines Follow Long History Of Failed Outcomes Trials
Wary Of Surrogates, Payers Seek Outcomes Data For PCSK9 Class
HPS2-THRIVE Post-Mortem: Lessons Learned For CV Drug Developers
HPS2-THRIVE Post-Mortem: Lessons Learned For CV Drug Developers
Dalcetrapib Failure Raises Yet More Questions On Value Of Tinkering With HDL Cholesterol
More Disheartening News For Abbott Cholesterol Franchise: Niaspan/Statin Study Halted Due To Lack Of Added Benefit

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055186

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel